Not provided
Not provided
Not provided
Not provided
Not provided
A fundamental protocol deviation on data capture left the database no longer fit for purpose.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Global PBC Study Group | UNKNOWN |
| Target RWE | INDUSTRY |
| Syneos Health | OTHER |
| UK PBC Study Group |
Not provided
Not provided
Not provided
Not provided
This is an observational, retrospective cohort study, using the UK PBC registry, comparing patients with primary biliary cholangitis (PBC) who failed ursodeoxycholic acid (UDCA) treatment and were treated with obeticholic acid (OCA) to patients with PBC who failed UDCA treatment and were not treated with second-line therapy. The study is designed to evaluate the effectiveness of OCA. All patients who meet diagnostic criteria for PBC in the database between 01 Jun 2015 and 31 Dec 2021 and who meet all eligibility criteria will be considered for this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OCA Treatment Group | PBC patients with a history of UDCA failure who initiated OCA in the study window (01 Jun 2015 to 31 Dec 2021) |
| |
| Control Group | PBC patients with a history of UDCA failure who were eligible but were not treated with OCA (or off-label fibrates) in the study window (01 Jun 2015 to 31 Dec 2021) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Obeticholic Acid 5 MG | Drug | once daily, oral administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to the first occurrence of the composite endpoint of all-cause death, liver transplant, or hepatic decompensation. | Time from index date to first occurrence of the composite endpoint events, assessed up to 62 months. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Time to the first occurrence of all-cause death | Time from index date to first occurrence of all-cause death, assessed up to 62 months. | |
| Time to the first occurrence of liver transplant | Time from index date to first occurrence of liver transplant, assessed up to 62 months. |
Key Inclusion Criteria:
Key Exclusion Criteria:
Not provided
Not provided
Not provided
All patients who meet diagnostic criteria in UK PBC registry between 01 Jun 2015 and 31 Dec 2021 and who meet the eligibility criteria will be considered for the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lynda Szczech, MD | Intercept Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Intercept Pharmaceuticals, Inc | San Diego | California | 92129 | United States |
Not provided
| ID | Term |
|---|---|
| D008105 | Liver Cirrhosis, Biliary |
| ID | Term |
|---|---|
| D002780 | Cholestasis, Intrahepatic |
| D002779 | Cholestasis |
| D001649 | Bile Duct Diseases |
| D001660 | Biliary Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C464660 | obeticholic acid |
Not provided
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
| Obeticholic Acid 10 MG | Drug | once daily, oral administration |
|
|
| Standard of Care: UDCA | Drug | No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record. |
|
| Time to first occurrence of hepatic decompensation | Time from index date to first occurrence of hospitalization for hepatic decompensation, assessed up to 62 months. |
| D004066 |
| Digestive System Diseases |
| D008107 | Liver Diseases |
| D008103 | Liver Cirrhosis |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |